Adrenocortical carcinoma (CCS) is a rare form of endocrine neoplasm, characterized by a high resistance to medical therapy and a significant tendency to relapse and metastasis.
One strategy to develop an effective therapy for ACC is the identification of some pathway useful as targets for innovative therapies. This strategy has never been used to fight ACC.
In this work, the expression and localization of HIF-1¿ will test in two cell lines deriving from adrenocortical carcinoma, H295R and SW-13. Subsequently, the biological effects induced by the silencing of the HIF1A gene will be investigated in the same models, in particular with reference to cell proliferation, glucose metabolism and invasiveness.